Advancing ADCs and Bispecifics Across Oncology and Immunology

Antibody-drug conjugates and bispecific antibodies are reshaping the future of targeted therapy in oncology and immunology. In this ONCOLife exclusive, Dr. Rafael Amado, Head of Global R&D at Zai Lab, shares how the company is advancing next-generation therapeutics in oncology. We explore the novel ADCs ZL-1310, and what sets it apart in the evolving landscape of targeted cancer therapy. You can follow this interview on LinkedIn by this link:>>>

Join us as we discuss Zai Lab’s global pipeline strategy, recent breakthroughs, and what’s next in their mission to address high unmet medical needs across disease areas.

Some of the key topics in this interview include:

✔️ The design and clinical promise of ZL-1310, Zai Lab’s novel ADC targeting solid tumors
✔️ How ZL-1310 differentiates from other ADCs and what sets its payload and linker apart
✔️ Preclinical insights and dual-targeting approach behind ZL-1503 in atopic dermatitis
✔️ The role of IL-13/IL-31 blockade in addressing both inflammation and pruritus
✔️ Zai Lab’s global R&D strategy and future plans for advancing ADCs and bispecifics